Your browser doesn't support javascript.
loading
Global Rotavirus and Pneumococcal Conjugate Vaccine Introductions and the Association With Country Disease Surveillance, 2006-2018.
Peck, Megan E; Hampton, Lee M; Antoni, Sebastian; Ogbuanu, Ike; Serhan, Fatima; Nakamura, Tomoka; Walldorf, Jenny A; Cohen, Adam L.
Afiliação
  • Peck ME; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Hampton LM; Monitoring and Evaluation, Gavi, the Vaccine Alliance, Geneva, Switzerland.
  • Antoni S; Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
  • Ogbuanu I; Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
  • Serhan F; Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
  • Nakamura T; Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
  • Walldorf JA; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Cohen AL; Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
J Infect Dis ; 224(12 Suppl 2): S184-S193, 2021 09 01.
Article em En | MEDLINE | ID: mdl-34469564
ABSTRACT

BACKGROUND:

To inform the introduction of pneumococcal conjugate vaccine (PCV) and rotavirus vaccine, the World Health Organization (WHO) established the Global Invasive Bacterial Vaccine-Preventable Disease Surveillance Network (GISN) and the Global Rotavirus Surveillance Network (GRSN) in 2008. We investigated whether participation in these networks or other surveillance was associated with vaccine introduction.

METHODS:

Between 2006 and 2018, among all WHO member states, we used multivariable models adjusting for economic status to assess (1) the association between surveillance for pneumococcal disease or rotavirus disease, including participation in GISN or GRSN and the introduction of the PCV or the rotavirus vaccine, respectively, and (2) the association between the rotavirus disease burden and the rotavirus vaccine introduction among 56 countries participating in GRSN from 2008 to 2018.

RESULTS:

Countries that participated in or conducted surveillance for invasive pneumococcal disease or rotavirus disease were 3.5 (95% confidence interval [CI], 1.7-7.1) and 4.2 (95% CI, 2.1-8.6) times more likely to introduce PCV or rotavirus respectively, compared to those without surveillance. Among countries participating in GRSN, there was insufficient evidence to demonstrate an association between countries with higher rotavirus positivity and vaccine introduction.

CONCLUSIONS:

Surveillance should be incorporated into advocacy strategies to encourage the introduction of vaccines, with countries benefiting from data from, support for, and coordination of international disease surveillance networks.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Pneumocócicas / Infecções por Rotavirus / Vigilância da População / Vacinas Conjugadas / Vacinas Pneumocócicas / Vacinas contra Rotavirus Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Pneumocócicas / Infecções por Rotavirus / Vigilância da População / Vacinas Conjugadas / Vacinas Pneumocócicas / Vacinas contra Rotavirus Idioma: En Ano de publicação: 2021 Tipo de documento: Article